Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa.

Variable responses to readthrough drugs in COL17A1 nonsense variants highlight the need for personalized therapies in junctional epidermolysis bullosa.

• Why it matters: Nonsense mutations in COL17A1 cause severe skin fragility in JEB, and current treatments lack effectiveness across different mutations, emphasizing the importance of tailored approaches.
• What they did: Researchers tested a panel of translational readthrough-inducing drugs (TRIDs) on patient-derived keratinocytes with various COL17A1 nonsense mutations and explored NOG as an enhancer of readthrough.
• The result: Findings demonstrate mutation-dependent responses to TRIDs and suggest that combining NOG with TRIDs could improve therapeutic strategies, paving the way for personalized treatments in JEB-C17.